Halozyme Therapeutics ROI - Return on Investment 2010-2025 | HALO

Halozyme Therapeutics return on investment for the quarter ending March 31, 2025 was 25.5.

  • Halozyme Therapeutics average return on investment for 2024 was 21.42, a 45.32% increase from 2023.
  • Halozyme Therapeutics average return on investment for 2023 was 14.74, a 44.73% increase from 2022.
  • Halozyme Therapeutics average return on investment for 2022 was 26.67, a 39.46% decline from 2021.

Roi - return on investment can be defined as an indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity.

Halozyme Therapeutics ROI - Return on Investment 2010-2025 | HALO

  • Halozyme Therapeutics average return on investment for 2024 was 21.42, a 45.32% increase from 2023.
  • Halozyme Therapeutics average return on investment for 2023 was 14.74, a 44.73% increase from 2022.
  • Halozyme Therapeutics average return on investment for 2022 was 26.67, a 39.46% decline from 2021.

Roi - return on investment can be defined as an indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity.